A review of teicoplanin in the treatment of serious neonatal infections

European Journal of Pediatrics

Volumn 156, Issue 6, 1997, Pages 423-427

  Fanos, V ^a   Kacet, N ^b   Mosconi, G ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIV LILLE   (France)

^c MMD European Medical Department   (Switzerland)

Author keywords

Gram positive; Neonatal infections; Sepsis; Teicoplanin

Indexed keywords

COAGULASE; TEICOPLANIN; VANCOMYCIN;

ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEWBORN INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; METHICILLIN RESISTANCE; SEPSIS; TEICOPLANIN;

EID: 0030992183     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004310050629     Document Type: Review

References (33)

1. Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, et al (1991) Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administrations to humans. J Pharm Sci 80:605-607
2. Baumgart S, Hall SE, Campos JM, Polin RA (1983) Sepsis with coagulase-negative staphylococci in critically ill newborns. Am J Dis Child 137:461-463
3. Brodgen RN, Peters DH (1994) Teicoplanin: a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:823-854
4. Campoli-Richards DM, Brodgen RN, Faulds D (1990) Teicoplanin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 40:449-486
5. Charbonneau P, Harding J, Garauda J, Aubertin J, Brunet T, Domart Y. (1994) Teicoplanin: a well tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients. Int Care Med 20:35-42
6. Chow AW, Azar RW (1994) Glycopeptides and nephrotoxicity Int Care Med 20:523-529
7. Davey PG, Williams AH (1991) A review of the safety profile of teicoplanin. J Antimicrob Chemother 27:475-480
8. Fanos V, Verlato G, Dal Moro A, Chiaffoni GP, Padovani EM (1995) Staphylococcus epidermidis isolation and antibiotic resistance in a Neonatal Intensive Care Unit. J Chemother 1:26-29
9. Fekety R (1990) Vancomycin and teicoplanin. In: Mandell GL, Douglas RG Jr, Benett JE (eds) Principles and practice of infectious diseases, 3 edn. Churchill Livingstone, New York, pp 317-323
10. Fischer GV (1992) Pediatric and neonatal infections. Curr Opin Infect Dis 5:551-595
11. Gotoff S (1992) Infections of the newborn. In: Behrman RE (ed) Textbook of pediatrics, 14 edn. WB Saunders, Philadelphia, pp 495-524
12. Gouyon JB, Franoise C, Semama D, Sandro D (1990) Septicemie nosocomiales a Staphylocoques epidermidis et aureus chez le nouveau-né. Ann Pediatrie 31:21-25
13. Guadagni AM, Quondamcarlo A, Mosconi G, Virgili Q, Mastrodicasa M (1993) Neonatal staphylococcal infections treated with teicoplanin. J Chemother 5 [Suppl 1]:485
14. Johnson AP, Uttley AHC, Woodford N, George RC (1990) Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev 3:280-291
15. Kacet N, Dubos JP, Roussel-Delvallez M, Storme L, Pierrat V, Rousseau S, Lequien P (1993) Teicoplanin and amikacin in neonates with staphylococcal infection. Pediatr Infect Dis J 12:S10-S20
16. Klein JO, Michael Mercy S, Mercy M (1995) Bacterial sepsis and meningitis. In: Remington JS, Klein J (eds) Infectious disease of the fetus and newborn infant. 4th edn. W.B. Saunders, Philadelphia, pp 835-878
17. Munson DP, Thompson ThR, Johnson DE, Rhames ES (1982) Coagulase-negative septicemia: experience in a newborn intensive care unit. J Pediatr 101:602-605
18. Neu HC (1992). The crisis in antibiotic resistance. Science 257:1064-1072
19. Padovani EM, Khoory BJ, Beghini R, Chiaffoni GP, Fanos V (1994) Teicoplanin: clinical efficacy, antibacterial activity and tolerance in the treatment of staphylococcal infections in the newborn. Ann Exp Clin Med 1:111-115
20. Papp CM, Nahata MC (1990) Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 19:280-318
21. Patrick CC, Kaplan SL, Baker CJ, et al (1989) Persistent bacteremia due to cogaulase-negative staphylococci in low birthweight neonates. Pediatrics 84:977-985
22. Payne NR, Schilling CG, Steinberg S (1994) Selecting antibiotics for nosocomial bacterial infections in patients requiring neonatal intensive care. Neonatal News 13:41-51
23. Ribner BS (1987) Endemic, multiply resistant Staphylococcus aureus in a pediatric population. Clinical description and risk factors. Am J Dis Child 141:1183-1187
24. Scarpelli G, Lucente M, Furlano A, Mari A, Gualtieri R (1993) Sepsi neonatali da stafilococco e teicoplanina [abstract]. 1st Congresso Nazionale di Pediatria Ospedaliera, Rome, January 14-16
25. Schwalbe RS, Stapleton JT, Gilligan PH (1987) Emergence of vancomycin resistance in coagulase-neeative staphylococci. N Engl J Med 316, 15:927-931
26. Serra G, Giovanni L, Bonacci W (1992) Le infezioni stafilococciche in epoca neonatale. Antibioticoterapia per la pratica 2:45-53
27. Spencer CM, Bryson HM (1995) Teicoplanin: a pharmacoeconomic evaluation of its use in the treatment of Gram-positive infections. PharmacoEconomics 7:357-374
28. Starr SE (1985) Antimicrobial therapy of bacterial sepsis in the newborn infant. J Pediatr 106:1043-1048
29. Tuo P, Tumolo M, Silvestri G, Vallarino R, Balzarini C, Barretta A, Mazzarello GF, Losurdo G, Mantero E, Fossa (1992) La terapia con teicoplanina in terapia intensiva neonatale e pediatrica (Teicoplanin therapy in neonatal and pediatric intensive care). Pediatr Med Chir:151-154
30. Van Lierde S, Vanhole C, Verbist L, Verhaegen J, Devlieger H (1995) Teicoplanin in neonatal nosocomial sepsis. 16th European Congress of Paediatric Infectious Diseases, Birmingham
31. Wallace MR, Mascola JR, Oldfield EC III (1991) Red man syndrome: incidence, etiology, and prophylaxis. JID 1, 164:1180-1185
32. Wilson APR, O'Hare MD, Felmingham D, Grunenberg RN (1986): Teicoplanin-resistant coagulase-negative staphylococcus. Lancet II:973
33. Wood MJ (1996) The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 37:209-222